GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » Cash, Cash Equivalents, Marketable Securities

Albert Labs International (XCNQ:ABRT) Cash, Cash Equivalents, Marketable Securities : C$0.00 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International Cash, Cash Equivalents, Marketable Securities?

Albert Labs International's quarterly cash, cash equivalents, marketable securities declined from Mar. 2023 (C$0.07 Mil) to Jun. 2023 (C$0.00 Mil) but then stayed the same from Jun. 2023 (C$0.00 Mil) to Sep. 2023 (C$0.00 Mil).

Albert Labs International's annual cash, cash equivalents, marketable securities increased from . 20 (C$0.00 Mil) to Dec. 2021 (C$0.08 Mil) and increased from Dec. 2021 (C$0.08 Mil) to Dec. 2022 (C$0.08 Mil).


Albert Labs International Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Albert Labs International's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International Cash, Cash Equivalents, Marketable Securities Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
Cash, Cash Equivalents, Marketable Securities
0.08 0.08

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.08 0.07 - -

Albert Labs International Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Albert Labs International  (XCNQ:ABRT) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Albert Labs International Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Albert Labs International's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Albert Labs International (XCNQ:ABRT) Business Description

Industry
Traded in Other Exchanges
N/A
Address
6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International (XCNQ:ABRT) Headlines

No Headlines